background: This study aimed to evaluate the potential benefit, in terms of pain relief, of the new oral fast-release orodispersible galvanic form of tramadol in women undergoing hysterosalpingography (HSG) with either a metal cannula or a balloon catheter.
Introduction
Hysterosalpingography (HSG) visualizes the delineation of the uterine and tubal cavities radiographically by transcervical injection of radiocontrast medium. The procedure aims to investigate the tubal patency and is therefore an integral part of the infertility workup. However, cervical instrumentation, uterine distension with contrast media or peritoneal irritation as a result of contrast spill into the peritoneal cavity often lead to pain or discomfort for the patient. In the literature, pain scores as assessed by visual analogue score on a scale from 0 to 10 during HSG without analgesia range from 5.9 to 6.8 (Kafali et al. 2003; De Mello et al., 2006) . A Cochrane review concluded that there was little evidence of benefit in terms of pain relief of any of the available analgesic interventions during and up to 29 min after HSG . Recently, a new galenic form of tramadol aimed at a rapid onset of the analgesic effect has been developed. The potential benefit in terms of pain relief of this new galenic form during HSG is unknown. Tramadol acts through a weak affinity for m-receptors and secondly by inhibiting noradrenalin and serotonin neuronal reuptake. It has been used since the 1970s by over 50 million people for the treatment of acute and chronic pain. The orodispersible tramadol tablet, a new galenic form, is a fast-release tablet that disintegrates rapidly in contact with saliva. Therefore, when the saliva is swallowed, the drug reaches the gastrointestinal tract. This galenic formulation is bioequivalent to the standard capsules but facilitates early treatment as it can be taken 30 min before an HSG. Its abuse potential is very low (Tagarro et al., 2004) .
Patients' comfort may also be influenced by the applied HSG device. Some studies conclude that flexible balloon catheters are superior to the traditional metal cannulas (Tur-Kapsa et al., 1998; De Mello et al., 2006) , whereas other trials did not observe differences in pelvic pain (Austin et al., 1984; Varpula, 1989) .
We therefore evaluated the analgesic effect of the orodispersible fast-release form of tramadol in HSG performed with either a metal cannula or a balloon catheter. This trial was a randomized, double-blind, placebo-controlled 2 × 2 factorial-design trial with parallel groups.
Materials and Methods

Design
This trial was performed at a single-centre university hospital between November 2008 and February 2009 (Universitair Ziekenhuis Brussel Protocol Record 2008 . The trial was approved by the ethics committee of the university hospital and all patients gave written informed consent. Patients with medical contraindications for tramadol, morphine or other opioids as well as for the use of monoamine oxidase inhibitors or other central nervous system-acting drugs were excluded from this study. Other exclusion criteria were allergy to radio-contrast medium, cervical stenosis, presence of pelvic inflammatory disease or any other condition causing pelvic pain. Patients' demographics and relevant medical history were collected before the procedure.
Power and sample size calculations were based on the visual analogue scales (VASs) score during the most painful step of the HSG procedure as reported by Cengiz et al. (2006) in a placebo-controlled randomized clinical trial. We assumed a most painful VAS score of 4.50 [standard deviation (SD) 1.70] in the control group, and we considered a 25% decrease to an overall VAS score of 3.38 (SD 1.31) in the active treatment arm as beneficial (Cengiz et al., 2006) . A computer-generated randomization table allocated 128 patients into four groups to receive either tramadol or placebo and to the use of either a metal cannula or a balloon catheter as the HSG device. Allocation was done by simple randomization. The patients were unaware of the type of cannula used and the medication received. Two patients were excluded before randomization ( 
Procedures
Patients were administered either 50 mg of fast-release orodispersible tramadol (Meda Pharma, Brussels, Belgium) or placebo 30 min before the procedure.
Patients underwent HSG with the contrast medium being instilled through either a metal cannula or a balloon catheter (Cook, Limerick, Ireland) . After speculum and vaginal antisepsis, placement of the tenaculum was coordinated with the patient giving a forceful cough. The metal cannula was gently inserted into the external cervical os. This was followed by injection of a water-soluble contrast medium (Hexabrix 320, Codali, Brussels, Belgium) under fluoroscopy. The patients randomized in the balloon catheter group had the balloon positioned without the placement of a tenaculum. The balloon was inflated at the uterine isthmus after fluoroscopic evaluation (Silberzweig, 2007) .
Pain evaluation
For the primary end-point, pain was scored using the 10-cm-long linear VAS. The scores were reported by all patients undergoing the procedure as well as by the clinician performing the procedure. Patients were asked to score the pain at five stages of the procedure: (1) speculum application, (2) cervical instrumentation, (3) uterine filling, (4) tubal spillage and (5) at 30 min after removal of the instrumentation. The cervical instrumentation included either balloon inflation or cervical grasping. Two additional time points for scoring of the pain were 6 and 24 h after the procedure [time points (6) and (7), respectively]. Secondary end-points included side effects and pain as assessed by the same physician during HSG. The physician performing the HSG procedure recorded a pain score only at the five different steps during the procedure. All examinations were performed on an outpatient basis by the same gynaecologist.
Statistical analysis
Baseline characteristics are presented as the number of cases and percentages for categorical data, and as means with SD for continuous data. All analyses were done by intention to treat.
The main effects of tramadol and the HSG device on VAS pain scores, as reported by the patient and as perceived by the physician, were analysed by general linear model repeated-measures ANOVA. All analyses were adjusted for differences in baseline characteristics and pain sensitizers. The interaction between the two main interventions (tramadol and HSG device) was also investigated.
For the other end-points, the groups were compared by using Fisher's exact test or x 2 techniques for categorical variables, and ANOVA for continuous variables. Outcomes were analysed on an intention-to-treat basis, and all tests were two-sided with an a level of 0.05. All data management and statistical analysis were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics and pain sensitizers
There were no statistically significant differences across the four groups with regard to age, the number of previous pregnancies, parity, and prevalence of past dysmenorrhoea, dyspareunia, abdominal surgery, dilatation and curettage, conization, vaginal delivery and Caesarean section. However, there was a statistically significant imbalance in terms of prevalence of past abortion (Table I) .
Pain Figure 2 and Table II present the results for the four separate treatment groups.
The main effects, estimated by the difference among marginal means, are shown in Table III . The main effect of tramadol versus placebo medication, i.e. metal cannula plus tramadol AND balloon catheter plus tramadol versus metal cannula plus placebo AND balloon catheter plus placebo, was a statistically significant difference (P , 0.001) in selfreported VAS of 20.91 (21.35 to 20.47) on the absolute, and 233% (248% to 217%) on the relative, scale in favour of tramadol. The main effect of the balloon catheter versus metal cannula, i.e. balloon catheter plus placebo AND balloon catheter plus tramadol versus metal cannula plus placebo AND metal cannula plus tramadol, was a non-significant (P ¼ 0.82) difference in patient-reported VAS of 20.05 (20.49 to +0.39) and 22% (221% to +17%). There was no medication*HSG device interaction (P ¼ 0.74). Likewise, there was a significant benefit for tramadol against placebo medication for physician-perceived VAS pain scores (39% relative reduction; P , 0.001), no difference in between the balloon catheter and the metal cannula (P ¼ 0.85), and no medication/HSG device interaction (P ¼ 0.22).
Further analyses adjusting for differences in baseline characteristics (Table I) indicated that these findings in terms of VAS pain scores remained essentially similar (data not shown).
Adverse outcome events
During the procedure, one patient in the tramadol group with metal cannula complained about nausea. Dizziness was observed in one patient in the metal cannula and placebo group, two patients in the balloon catheter and placebo group, and one patient in the balloon catheter with tramadol group. The number of these events was too small for further analysis. There were no other adverse events during the procedures.
Radiographic findings
No major differences were found in terms of pathological findings for unilateral or bilateral tubal obstruction (Table IV) . Interestingly, however, intracavitary polyps or myomas were coincidentally significantly more prevalent in the groups using a metal cannula. No congenital uterine malformations were diagnosed in any of the four groups.
Additional analyses adjusting for differences in prevalence of intracavitary polyps or myomas indicated that our conclusions regarding VAS pain scores remained unchanged (data not shown).
Discussion
The design of the present study was meant to evaluate the analgesic effect of orodispersible tramadol in HSG with the use of either a metal cannula or a balloon catheter, and any potential interaction as well. Orodispersible tramadol reduced the pain scores reported by the patient and perceived by the physicians, without any increased incidence in adverse events. We found no differences in pain scores between the use of the metal cannula and the balloon catheter.
The use of a placebo control group is appropriate as there is no consensus whether or not to administer analgesia during HSG, and, if so, which analgesia is to be considered and when this analgesic is to be administered .
A literature search reveals only one randomized controlled trial (RCT) evaluating the use of an oral opioid analgesic during HSG. The study was not placebo controlled as it compared the effectiveness of oral tramadol 100 mg versus a non-steroidal anti-inflammatory drug (NSAID) (Naproxen 500 mg) administered 30 min before the procedure (Peters et al., 1996) . It indicated that there is no evidence of a preferential effect of tramadol for pain relief. Moreover, complaints of dizziness and nausea occurred significantly more often in the tramadol group. In our trial, the use of orodispersible formulation of tramadol did result in a reduced pain score without an increased incidence of adverse events. As opposed to the oral tablet, the orodispersible tramadol tablet disintegrates rapidly (in around 20 -30 s) and may be taken without water. Pregastric absorption leads to a quicker onset of action, which may explain why the orodispersible formulation in the present study resulted in significantly lower pain scores.
Two RCTs evaluated the use of opioid analgesia by intravenous administration (Cengiz et al., 2006; Bello et al., 2008) . Cengiz et al. compared remifentanil (62 cases) analgesia with placebo as a control. They did find a significant reduction in pain during and after the procedure. However, special care is needed as one patient developed apnoea during this study. The resultant costs make this intervention unfeasible for outpatient use. The orodispersible formulation has, in contrast to intravenous opioids, a negligible respiratory depressant effect. The other RCT compared the analgesic effect of tramadol premedication with that of butylbromide in HSG, both administered intravenously (Bello et al., 2008) . No significant difference in pain scores were noticed. The parenteral bolus administration in both of these trials may produce cognitive impairment and affects the driving ability thus limiting its use in an outpatient setting.
The pain caused by the HSG procedure can be typically intense over a short period and is therefore difficult to treat with a relatively weak analgesic. Various pharmacological strategies for analgesia during and after an HSG procedure have been studied in RCTs: paracetamol (Owens et al., 1985; Elson and Ridley, 2000) , oral NSAID (Lorino et al., 1990; Peters et al., 1996; Anserini et al., 2008) , oral aspirin (Owens et al., 1985) , oral opioid (Peters et al., 1996) Time points: (1) speculum application, (2) cervical instrumentation, (3) uterine filling, (4) tubal spillage, (5) 30 min after speculum removal, and also 6 and 24 h after the procedure, i.e. time points (6) and (7) (1) speculum application, (2) cervical instrumentation, (3) uterine filling, (4) tubal spillage, (5) 30 min after speculum removal, and also 6 and 24 h after the procedure [time points (6) and (7) (De Mello et al., 2006) , topical analgesia (Lorino et al., 1990; Costello et al., 2002; Kafali et al., 2003; Frishman et al., 2004; Liberty et al., 2007) and intrauterine local anaesthetic (Jacobs et al., 1991) .
A recent meta-analysis concludes that there's little evidence of benefit in terms of pain relief of any of the interventions during and up to 29 min after HSG . Reduced delayed pain was noted after using local analgesia, 30 min after the procedure. A more recent randomized placebo-controlled trial, and therefore not considered in the meta-analysis, concluded that the cervical application of EMLA cream reduces the pain also during the procedure (Liberty et al., 2007) . This form of analgesia necessitates the application of a cervical cap with the local anaesthetic for 30 min prior to the procedure. In standard day-to-day clinical practice, a frequently used form of analgesia is NSAID (Baramki, 2004) , a practice mainly based on one randomized placebo-controlled study dated back 1985 showing, on a small set of cases (45 cases), the efficacy of fenoprofen in reducing pain during and after HSG (Owens et al., 1985) . Larger studies with other NSAIDs conclude that there is no difference (440 cases; nimesulide 100 mg) in pain score or that naproxen (180 cases, 550 mg) is effective only when associated with other analgesic procedures (Lorino et al., 1990; Anserini et al., 2008) . A Cochrane review by Ahmad et al., (2008) therefore concludes that NSAID should only be used during clinical trials.
Several RCTs have been performed comparing the use of a balloon catheter with a metal cannula for HSG (Austin et al., 1984; Varpula, 1989; Tur-Kapsa et al., 1998; de Mello et al., 2006) . Although initial studies did not observe a difference in patients' comfort (Austin et al., 1984; Varpula, 1989) , more recent trials observed significantly better pain scores for the balloon catheter. Tur-Kapsa et al. observed that the balloon catheter successfully prevents reflux of contrast back into the vagina, resulting in smaller amount of contrast required and faster visualization with significantly less fluoroscopic time. The authors argue that the significant reduction of pain is attributed to the use of a smaller amount of contrast agent and the absence of tenaculum use. In the current trial, we did not find a significant difference in the pain scores between the use of the metal cannula and the balloon catheter. Moreover, we observed the highest pain scores in the step of tubal filling (3) and tubal spillage (4) and not during cervical grasping (2) as in studies with a favourable outcome for the balloon catheters (TurKapsa et al., 1998; de Mello et al., 2006) or local cervical analgesia (Liberty et al., 2007) . The limited contribution of the pain in the cervical instrumentation step (2) to the overall pain score and the absence of reduced pain in the absence of tenaculum insertion explains the similarity in pain curves between the balloon catheter and the metal cannula groups. However, inflating the balloon at the cervical isthmus rather than in the cervical canal may have altered the discomfort for the patient (Silberzweig, 2007) . Reduced pain caused by a modification in the application of the balloon catheter group could therefore alter the benefit of administering tramadol. Differences between patient characteristics may limit the comparability of pain scores between the medication groups or the HSG devices. Despite a computerized randomization procedure, our trial groups were not perfectly balanced regarding pain sensitizers and the number of women in each group. More specifically, there was an imbalance in terms of prevalence of past abortion and intracavitary polyps or myomas. Peak pain during tubal filling and spillage may therefore be due to higher intrauterine pressure resulting from the hampered contrast outflow. Statistical methods taking into account these imbalances indicated that our results in terms of pain were not affected by these imbalances. To keep the numbers of women in the different groups as equal as possible, we should have used block (or restricted) randomization, rather than simple randomization. However, it is very unlikely that another randomization procedure might have changed our main conclusions.
In conclusion, this trial demonstrates the analgesic potential of an orodispersible opioid tablet in outpatient HSG. Pain reduction is achieved in the HSG procedures performed both with a metal cannula or with a balloon catheter. The orodispersible tablet is well tolerated and the side effects associated with this new galenic formulation are rare. Further research needs to evaluate the use of this form of analgesia in other potentially painful procedures such as hysteroscopy, curettage or oocyte retrievals.
